Abstract:e15572 Background: Therapies targeting immune checkpoints, such as the programmed cell death-1 (PD-1) / programmed cell death ligand 1 (PD-L1) pathway, have become successful in treating several cancer types, particularly those with high PD-L1 expression. Patient response rates, however, are variable, demanding a more sensitive companion diagnostic test than the current method of manual scoring of PD-L1 immunohistochemistry images. The low predictive value of manual PD-L1 scoring is at least partially compounded by the pathologist-to-pathologist or hospital-to-hospital variation. To eliminate the variation caused by human factors, we developed an alternative PD-L1 scoring method based on automated image analysis and assessed its predictive and prognostic values. Methods: Archival or fresh tumor biopsies were analyzed for PD-L1 expression by immunohistochemistry. Digital images were automatically scored as PD-L1 positive or negative using a custom algorithm implemented in Python and Tensorflow, which uses a fine-tuned, ImageNet pre-trained, Inception-ResNet-V2 model as the binary classifier along with a modified U-net image segmentation model to determine the final prediction. Supervised machine learning was used to control for heterogeneity introduced by PD-L1 positive inflammatory cells in the tumor microenvironment. Samples from 256 patients were collected and used in algorithm training and verification by random assignment with an 8:2 split ratio. Results: In total, 10,000 images with balanced PD-L1 positive and negative distributions were obtained. A highly significant correlation of PD-L1 scores was found between pathologist-based consensus reading and automated analysis using our custom algorithm (R = 0.97, p < 0.0001). The automated analysis reached 0.94 sensitivity and 0.96 specificity. Additionally, it showed excellent reproducibility (R = 1.0, p < 0.0001) in independent trials executed on different workstations, which is far superior to the manual scoring performed by human examiners. Conclusions: Our automated PD-L1 evaluation algorithm significantly reduces scoring variability. It may help to identify cancer patients who can have optimal response to PD-1/PD-L1 related immune therapy and therefore facilitate patient stratification in clinical practice.

A Quantitative Analysis Platform for PD-L1 Immunohistochemistry Based on Point-level Supervision Model.

PD-L1 Prediction of Lung Cancer by a Radiomics Method Using Rough Tumor Mask in CT Images

Application of Automated Segmentation and Classification of PD-L1 Immunohistochemistry Images in Cancer Treatment Prediction.

Prediction of PD-L1 tumor positive score in lung squamous cell carcinoma with H&E staining whole slide images and deep learning

Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images

Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer

A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry

A Deep Learning Diagnostic Platform for Diffuse Large B-cell Lymphoma with High Accuracy Across Multiple Hospitals

Unsupervised Domain Adaptive Tumor Region Recognition for Ki67 Automated Assisted Quantification.

Deep learning-based instance segmentation for the precise automated quantification of digital breast cancer immunohistochemistry images

Deep learning-based image analysis predicts PD-L1 status from H&E-stained histopathology images in breast cancer

Deep Semi Supervised Generative Learning for Automated PD-L1 Tumor Cell Scoring on NSCLC Tissue Needle Biopsies

Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images

Artificial intelligence-based assessment of PD-L1 expression in diffuse large B cell lymphoma

Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma

Association of Artificial Intelligence-Powered and Manual Quantification of Programmed Death-Ligand 1 (PD-L1) Expression with Outcomes in Patients Treated with Nivolumab ± Ipilimumab

AI-Powered Segmentation of Invasive Carcinoma Regions in Breast Cancer Immunohistochemical Whole-Slide Images

Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer